Recent News

• 06.25.2025 - Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
• 06.24.2025 - Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement
• 06.10.2025 - Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split
• 05.28.2025 - Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025
• 05.14.2025 - Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

Recent Filings

• 06.18.2025 - EFFECT Notice of Effectiveness
• 06.18.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 06.12.2025 - 8-K Current report
• 06.11.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 06.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.11.2025 - S-3 Registration statement under Securities Act of 1933
• 06.11.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 06.09.2025 - 8-K Current report
• 06.02.2025 - 8-K Current report
• 05.15.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors